Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Nucleozin is a novel potent antivirus agent that targets influenza A nucleoprotein (NP), which is a multifunctional, RNA-binding protein necessary for virus replication. Nucleozin is effective in fighting H1N1, H3N2, and H5N1 flu virus strains by inducing the formation of NP aggregates and antagonizing its nuclear accumulation, leading to cessation of viral replication. As influenza viruses have developed resistance towards current drugs, new inhibitors that prevent viral replication through different inhibitory mechanisms (e.g. targeting the influenza A nucleoprotein) are useful.
ln Vitro |
Nucleozin impedes the infection of influenza A/WSN/33, H3N2, and Vietnam/1194/04 (H5N1) in MDCK cells, with EC50 values of 0.069 μM, 0.16 μM, and 0.33 μM in the plaque reduction assay (PRA), correspondingly. In multicycle growth assays, nucleozin completely inhibits virus production at 1 μM and severely suppresses viral growth at 0.1 μM.
|
---|---|
ln Vivo |
Mice exposed to fatal doses of avian influenza A H5N1 are shielded by nucleozin[1].
|
References |
Molecular Formula |
C21H19N4O4CL
|
---|---|
Molecular Weight |
426.85296
|
Exact Mass |
426.11
|
Elemental Analysis |
C, 59.09; H, 4.49; Cl, 8.30; N, 13.13; O, 14.99
|
CAS # |
341001-38-5
|
Appearance |
Solid powder
|
SMILES |
O=C(N1CCN(C2=CC=C([N+]([O-])=O)C=C2Cl)CC1)C3=C(C)ON=C3C4=CC=CC=C4
|
InChi Key |
OWXBJAPOSQSWAO-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C21H19ClN4O4/c1-14-19(20(23-30-14)15-5-3-2-4-6-15)21(27)25-11-9-24(10-12-25)18-8-7-16(26(28)29)13-17(18)22/h2-8,13H,9-12H2,1H3
|
Chemical Name |
1-(2-Chloro-4-nitrophenyl)-4-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]-piperazine
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 15~20 mg/mL ( 35.14~46.85 mM)
|
---|---|
Solubility (In Vivo) |
10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2 mg/mL (4.69 mM) (Please use freshly prepared in vivo formulations for optimal results.)
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3427 mL | 11.7137 mL | 23.4274 mL | |
5 mM | 0.4685 mL | 2.3427 mL | 4.6855 mL | |
10 mM | 0.2343 mL | 1.1714 mL | 2.3427 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Chemical structures and biological activities of nucleozin and related compounds. [1].Nat Biotechnol. 2010;28(6):600-605. td> |
Influenza A NP is the molecular target of nucleozin. [1].Nat Biotechnol. 2010;28(6):600-605. td> |
Nucleozin interacts with NP and causes NP aggregation. [1].Nat Biotechnol. 2010;28(6):600-605. td> |
Efficacies of nucleozin in a mice H5N1 virus infection model. [1].Nat Biotechnol. 2010;28(6):600-605. td> |